此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MacTel 2 型患者的丝氨酸和非诺贝特研究 (SAFE)

2026年8月25日 更新者:The Lowy Medical Research Institute Limited

补充丝氨酸和非诺贝特治疗对 2 型黄斑毛细血管扩张症 (MacTel) 患者血清脱氧二氢鞘氨醇水平影响的 2a 期研究(SAFE 研究)

This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.

研究概览

详细说明

Additional Procedures include:

  1. Fasting blood work
  2. Collection of microbiome samples

研究类型

介入性

注册 (实际的)

89

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
    • Michigan
      • Ann Arbor、Michigan、美国、48105
        • Kellogg Eye Center, University of Michigan
    • Ohio
      • Cleveland、Ohio、美国、44122
        • Retina Associates of Cleveland
    • Tennessee
      • Knoxville、Tennessee、美国、37922
        • Southeastern Retina Associates
    • Texas
      • Bellaire、Texas、美国、77401
        • Retina Consultants of Texas
    • Utah
      • Salt Lake City、Utah、美国、84132
        • Moran Eye Center, University of Utah
    • Washington
      • Seattle、Washington、美国、98104
        • University of Washington
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • The Eye Institute, Medical College of Wisconsin
      • London、英国、ECV2PD
        • Moorfields Eye Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
  2. Males/females 21 years of age or older;
  3. English speaking;
  4. Enrolled in the Natural History Observation and Registry Study (NHOR) and diagnosed with confirmed MacTel type 2 in at least one eye;
  5. Willing to use contraception, if applicable; and
  6. Willing to comply with study protocol and follow-up visits.

Exclusion Criteria:

  1. Participant is unable to provide informed consent;
  2. Participant is less than 21 years of age;
  3. Participant is currently taking, or has taken within four weeks prior to screening, a serine or glycine supplement;
  4. Participant is currently taking, or has taken within 12 months prior to screening, fibrates including clofibrate, ciprofibrate, bezafibrate, fenofibrate, and gemfibrozil;
  5. Participant is currently taking an anticoagulant, colchicine, cyclosporine, tacrolimus or bile acid binding resins;
  6. Participant has known allergy to fibrates and/or serine;
  7. Participant has a known history of clinically significant myopathy or myalgia related to cholesterol-lowering drugs;
  8. Participant has active liver disease and/or elevated liver enzymes*;
  9. Participant has renal dysfunction as evidenced by elevated serum creatinine* and/ or glomerular filtration rate (GFR) less than 90 mL/min;
  10. Participant has thrombocytopenia as evidenced by a platelet count below 100,000 per microliter, anemia as evidenced by hemoglobin levels below 10 g/dL, or history of bleeding disorder;
  11. Participant has a history of gallbladder disease or has had a cholecystectomy;
  12. Participant has triglyceride levels greater than 400 mg/dL on treatment, or greater than 700 mg/dL on no treatment;
  13. Participant has untreated/uncured Hepatitis C, or a history of Hepatitis B, autoimmune hepatitis, or HIV;
  14. Participant has had any malignancies within the last 5 years (not including basal cell carcinoma);
  15. Participant has ever been enrolled in a clinical trial involving ciliary neurotrophic factor (CNTF) treatment;
  16. Participant is currently enrolled in another clinical trial that involves treatment or participated in one within the last 30 days;
  17. Participant is pregnant, breastfeeding or planning a pregnancy;
  18. Participant is medically unable to comply with study procedures or follow-up visits;
  19. Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments; or
  20. Patient is unavailable for follow-up visits. *based on reference range for the local laboratory used

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Serine 200 mg/kg/day

Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

实验性的:Serine 400 mg/kg/day

Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

实验性的:Fenofibrate 160 mg/day

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Fenofibrate 160mg pill, taken orally

实验性的:Serine 200 mg/kg/day and Fenofibrate 160 mg/day

Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Fenofibrate 160mg pill, taken orally

实验性的:Serine 400 mg/kg/day and Fenofibrate 160 mg/day

Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Fenofibrate 160mg pill, taken orally

无干预:No treatment

Control group: no investigational product taken

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Assessment
大体时间:Reported over the10 weeks from baseline to exit visit

Safety assessment measured via examined AEs and SAEs (during study visits) and via participant self-reported AEs and SAEs that occurred between visits

Reported over the10 weeks from baseline to exit visit
Percentage Change of Serum Deoxysphingolipid Levels From Baseline to 6 Weeks
大体时间:Blood draw at baseline and 6 weeks on product

Percentage change in the sum of 7 different deoxy-dihydroceramides species detected. Negative values mean these metabolites decreased during the treatment period. Deoxy-sphingolipids were measured in serum using LC-MS.

Blood draw at baseline and 6 weeks on product

次要结果测量

结果测量
措施说明
大体时间
Percentage Change in Serum Lipid Levels From Baseline to 6 Weeks
大体时间:blood draws from baseline and week 6 on product

Percent changes in lipid levels measured between baseline and 6 weeks. These lipid levels were obtained from the local clinical lab at each site as part of a lipid panel. Negative values mean these metabolites decreased during the treatment period.

blood draws from baseline and week 6 on product
Percentage Change in Serum Serine and Glycine Levels From Baseline to 6 Weeks
大体时间:blood draws from baseline and week 6 on product

Percentage change in fasting levels of the two amino acids serine and glycine. Serine supplementation is part of the treatment and glycine can be produced from serine by different cells in the body. Serine and glycine levels were measured from serum using LC-MS.

blood draws from baseline and week 6 on product

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mari A Gantner, PhD、Lowy Medical Research Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年4月7日

初级完成 (实际的)

2024年9月30日

研究完成 (实际的)

2024年9月30日

研究注册日期

首次提交

2021年5月25日

首先提交符合 QC 标准的

2021年5月25日

首次发布 (实际的)

2021年5月28日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年8月25日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅